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An effective human immunodeficiency virus type 1 (HIV-
1) vaccine is the best solution for halting the acquired 
immune deficiency syndrome epidemic. Here, we 
describe the design and preclinical immunogenicity of 
T-cell vaccine expressing novel immunogens tHIVconsvX, 
vectored by DNA, simian (chimpanzee) adenovirus, and 
poxvirus modified vaccinia virus Ankara (MVA), a combi-
nation highly immunogenic in humans. The tHIVconsvX 
immunogens combine the three leading strategies for 
elicitation of effective CD8+ T cells: use of regions of HIV-1 
proteins functionally conserved across all M group viruses 
(to make HIV-1 escape costly on viral fitness), inclusion of 
bivalent complementary mosaic immunogens (to maxi-
mize global epitope matching and breadth of responses, 
and block common escape paths), and inclusion of 
epitopes known to be associated with low viral load in 
infected untreated people (to induce field-proven pro-
tective responses). tHIVconsvX was highly immunogenic 
in two strains of mice. Furthermore, the magnitude and 
breadth of CD8+ T-cell responses to tHIVconsvX-derived 
peptides in treatment-naive HIV-1+ patients significantly 
correlated with high CD4+ T-cell count and low viral load. 
Overall, the tHIVconsvX design, combining the mosaic 
and conserved-region approaches, provides an indisput-
ably better coverage of global HIV-1 variants than pre-
vious T-cell vaccines. These immunogens delivered in a 
highly immunogenic framework of adenovirus prime and 
MVA boost are ready for clinical development.
Received 6 July 2015; accepted 31 December 2015; advance online  
publication 9 February 2016. doi:10.1038/mt.2016.3
Traditional vaccine approaches using killed or live attenuated 
virus cannot be used for human immunodeficiency virus type 1 
(HIV-1), and so subunit vaccines are favored.1,2 They employ HIV-
1-derived immunogens, which determine the specificity of the 
vaccine-elicited responses, and effective responses must contend 
with HIV-1 variability.3 Combinations of vaccine modalities are 
used to present the immunogens to the immune system, influenc-
ing the magnitude, type, location and durability of the elicited 
effector functions, and subsequent immunological memory. The 
quality of both the immunogens and their delivery is critical to 
achieve protective immunity: suboptimal design of either may 
cause vaccine failure.
The best HIV-1 vaccine strategy will likely involve induc-
tion of both broadly neutralizing antibodies and effective CD8+ 
T cells. The path to each requires different approaches, therefore 
most studies focus on developing T cell- and broadly neutralizing 
 antibody-vaccine strategies separately, before ultimately combin-
ing into one field vaccine. Meanwhile, either type of vaccine alone, 
if effective, could decrease HIV-1 spread and benefit infected 
individuals. In humans, the protective role of T cells is supported 
indirectly by detection of HIV-1-specific CD8+ T cells in HIV-1-
exposed seronegative subjects,4 the kinetics of early partial con-
trol of viremia as the first CD8+ T-cell responses appear, extensive 
virus escape in targeted epitopes5,6, and the protective effects of 
certain human leukocyte antigen (HLA) class I allotypes.7 Model 
vaccine and simian immunodeficiency virus-challenge stud-
ies in rhesus macaques have provided direct evidence that CD8+ 
T cell-vaccine responses can improve viral control and outcome in 
infected animals in a traditional vaccine setting8 and, remarkably, 
vaccine-elicited CD8+ T cells can both protect9 and clear10 simian 
immunodeficiency virus infection when elicited using a particular 
molecular clone of cytomegalovirus vector.
Currently, there are three leading strategies for antigen design 
for induction of effective anti-HIV-1 CD8+ T-cell responses. 
In the first strategy, in silico-designed multivalent-mosaic pro-
teins efficiently capture the most common epitope variants in 
the Los Alamos National Laboratory HIV Sequence Database 
 (LANL-HSD, www.hiv.lanl.gov).11 In the nonhuman primate 
model, full-length protein mosaic vaccines induced CD8+ and 
CD4+ T-cell responses of higher magnitude, greater breadth and 
cross-reactivity than either consensus-based or natural-protein 
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vaccines against peptides representing diverse natural strains.12–14 
Nevertheless, the use of full-length proteins only partially 
addresses HIV-1 diversity and escape, because efficacy is likely to 
be compromised by the inclusion of variable immunodominant 
and less protective regions.1 In the second strategy, we and Mullins 
et al.1,15–17 hypothesized that focusing vaccine-elicited T cells on 
the most conserved regions of HIV-1 proteins would be benefi-
cial because mutations in these regions are more likely to cause 
replicative fitness loss,18–21 and conserved epitopes are common to 
most HIV-1 variants, both within- and between clades, offering 
the potential for broad protection against diverse natural strains 
and global deployment. We pioneered the approach using 14 
highly conserved consensus regions of HIV-1 proteins assembled 
into a chimeric immunogen HIVconsv.15 When delivered in com-
binations of plasmid DNA, nonreplicating simian (chimpanzee) 
adenovirus (ChAdV) serotype 63, and nonreplicating poxvirus 
modified vaccinia virus Ankara (MVA), HIVconsv induced high 
frequencies of oligofunctional HIV-1-specific T cells capable of 
inhibiting HIV-1 replication in autologous CD4+ cells in vitro.22,23 
The third strategy selects beneficial CD8+ T-cell epitopes that are 
associated with low viral load, based on data from ~1,000 HIV-1 
clade-B and C-infected individuals.24 Beneficial epitopes assem-
bled into a vaccine immunogen have induced broad CD8+ T-cell 
responses in preclinical models.25
Our first-generation conserved-region vaccine15 provided 
the proof of concept that taking subdominant conserved regions 
out of the context of full-length proteins/HIV-1 and deliver-
ing them by a potent ChAdV-MVA regimen can induce robust 
human immune responses (re)focused on conserved epitopes22,23 
(and T.H., unpublished). Furthermore, the elicited T cells could 
recognize and kill autologous HIV-1-infected cells, where the 
epitopes were expressed in the context of natural HIV-1 pro-
teins.22,23 Encouraged by this foundational work, here we designed 
a  second-generation vaccine also focusing on functionally con-
served regions, but improved by incorporating advances made 
in the intervening years since our original conserved vaccines 
design in 2005. Thus, the main improvement is in combining 
the three above-mentioned T-cell approaches into one strategy 
as conserved bivalent-mosaic immunogens, designated tHIV-
consvX, which have a superior coverage of global HIV-1 vari-
ants to any previous vaccine approach. This second-generation 
design also benefited from the information gained by the clini-
cal testing of the original HIVconsv vaccine as well as by natural-
infection studies defining epitopes that are associated with viral 
control. The tHIVconsvX vaccines are vectored by plasmid DNA, 
ChAdOx126, and MVA. Collectively, the very high immunogenic-
ity of the first-generation vaccine in humans23 (and T.H., unpub-
lished), the highly rational in silico immunogen design, the strong 
preclinical overall immunogenicity in mice, and the demonstra-
tion that  tHIVconsvX-specific CD8+ T cells correlated with high 
CD4+ T-cell count in untreated patients strongly argue for timely 
clinical development of this novel, global T-cell vaccine approach.
RESULTS
Design of the tHIVconsvX immunogens
Open-reading frames (ORFs) of up to ~2.7 kbp can be easily 
inserted into commonly used vaccine vectors and support high 
protein expression. Thus, we aimed to include conserved regions 
totaling ~900 amino acids (aa), ~28% of the HIV-1 proteome, 
while minimizing the number of junctional regions and maximiz-
ing the number of beneficial epitopes.24 Our final second-gener-
ation vaccine was 872 aa in length, well within the range of the 
vector capacities, and contained only six fragments. In contrast, 
the first generation was 778 aa long and contained 14 fragments, 
and thus had many more junctional domains. The LANL-HSD 
curated global-HIV-protein alignments, circa September 2013, 
were used as the baseline data to define conserved regions. These 
alignments included only one sequence per individual, and 
only sequences spanning full-length proteins. The alignments 
were “cleaned” to exclude all proteins with frame-shifting muta-
tions or uncertain aa calls, leaving 1,800–3,600 sequences per 
protein. Cooptimized, complementary pairs of two mosaic pro-
teins were designed,11 spanning each HIV-1 protein (Figure 1a). 
Conservation was defined by the capacity of the two mosaic pro-
teins to have a perfect 9/9-aa match to at least 80% of the poten-
tial T-cell epitope (PTE) variants found among the diverse HIV-1 
strains in the LANL-HSD alignments; the 80% cutoff translated 
into a design of six fragments from 29 to 333 aa long. Next, both 
beneficial and bad epitopes as defined by Mothe et al.24 were over-
laid on vaccine epitope coverage maps for the final selection of 
regions for the second-generation conserved vaccine based on 
all criteria above, and we included only regions that were both 
conserved and enriched for beneficial epitopes. Thus, our second-
generation vaccine contained 33 of the 48 beneficial epitopes 
defined by Mothe et al.24 (69%)—the missing 15 beneficial epit-
opes were in variable regions in p17 and Vif; in contrast, our origi-
nal design only contained only 14 (29%) beneficial epitopes. The 
six regions we used included the whole of Gag p24, one region 
in Gag p15 and four regions of Pol overlapping with protease, 
polymerase, and integrase (Figure 1a,b). As a trade-off between 
fragment length and coverage, very short stretches of modestly 
increased 9-mer diversity were tolerated. In contrast, the original 
vaccine matched only 66% of the PTE regions spanned by the vac-
cine regions (Figure 2a; see Supplementary Figures S1 and S2 
for more detail). The improvement in PTE coverage in the second 
generation was due to two factors. First, the second-generation 
vaccine spanned more conserved regions than our original vac-
cine (Figure 2b). Second, the inclusion of two mosaic sequences, 
which provides the two most common forms of each 9-mer as the 
protein region traversed, enables much greater coverage of natu-
ral diversity by the vaccine (Supplementary Figures S1 and S2). 
Supplementary Figure S3 provides a simple summary of diver-
sity and coverage of three representative epitopes with different 
levels of diversity, to provide a more intuitive view of the implica-
tions of including bivalent vaccine in terms of improved coverage 
of HIV-1 diversity.
Env was deliberately excluded from the second-generation 
design; it has a short conserved stretch, but carries no beneficial 
epitopes.24 Often after vaccination, Env specificity has dominated 
anti-HIV-1 T-cell responses, yet Env-specific T cells have never 
been associated with good virus control.24,27–30 Also excluded were 
several highly conserved regions that contained only unfavourable 
epitopes, and regions that densely populated with beneficial epit-
opes but were variable, e.g., Gag p17 and Vif (Figure 1a). Finally, 
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Figure 1 Definition of the second-generation conserved regions employed in tHIVconsvX. (a) Global HIV-1 protein alignments taken from the 
LANL-HSD were used to design complementary bivalent mosaics for each protein spanning the full proteome, as described previously.11 The epitope 
coverage plots show, on the y-axis, the fraction of PTEs in the alignment that are matched by one of the two 9-mers in the mosaic pair; the fractions 
with a 9/9 and 8/9 matches are shown in red and orange, respectively. The x-axis tracks along the protein alignment, such that column that contains 
the first nine positions in an alignment (positions 1–9) is used to provide the coverage data shown in the left-most point, then the second 9-mer col-
umn that contains positions 2–10 provides the data for the next point, etc. The black dashed line shows the sum of the frequencies of the two most 
common 9-mers in each position. The purple bars above the graphs and the blue boxes illustrate the location of the 14 regions included, which are 
used in the first-generation conserved HIVconsv immunogen and the 6 regions in the second-generation tHIVconsvX immunogens, respectively. The 
small squares show the beneficial (green, modest reduction in viral loads, and blue more dramatic reductions in viral loads) and bad (grey) epitopes.24 
The shades of blue and green indicate the cohort, in which the associations were found: Spain, Peru, and South Africa. (b) Six regions (blue) of HIV-1 
Gag and Pol chosen to compose the tHIVconsvX immunogens with aa positions indicated above and below.
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while the boundaries of our conserved regions were defined based 
on 9-mer coverage, the precise boundaries were confirmed by per-
position Shannon entropy scores.31 We also confirmed that each 
conserved region was richly populated with validated human 
CD8+ and CD4+ T-cell epitopes (Supplementary Figure S4). Part 
of our motivation in maximizing the immunogen length poten-
tial of the vaccine is that an effective vaccine will not only have 
to contend with HIV-1 diversity, but will need to accommodate 
global human HLA class I diversity as well, hence we focused on 
epitope-dense regions. Based on the LANL epitope database, as of 
June 2015, 752 distinct epitopes have been experimentally defined 
in the literature within the boundaries of six conserved regions 
we included. These epitopes utilized 84 different HLA class I pre-
senting molecules, a consequence of including some of the most 
epitope-rich regions of the viruses. While these numbers, based 
on the database summary of the literature, emphasize the rich 
immunogenic potential of the conserved regions we selected, we 
fully expect these regions will contain many as yet undescribed 
epitopes.17 The aa sequences of the tHIVconsvX mosaic 1 and 
mosaic 2 differ in about 10% aa (Supplementary Figure S5).
Minimizing responses to possible junctional epitopes 
by reordering regions
Unnatural junctions between adjacent regions are an unavoid-
able feature of chimeric proteins. Up to 20% of HIVconsv-specific 
T  cells induced by the first-generation immunogen recognized 
junctional epitopes.23 This is not a major concern as long as suf-
ficiently broad anti-HIV-1 responses are also induced (note 
that many MVA and ChAdV vector-specific responses are elic-
ited, too), and there are no significant matches to proteins in the 
human proteome. Nevertheless, we aimed to minimize induc-
tion of irrelevant junction-specific responses, and so included 6 
larger fragments that spanned a few variable positions, rather than 
14 small conserved regions. We also scrambled the conserved 
regions in different orders into six immunogens designated from 
tHIVconsv1 to tHIVconsv6 (collectively called tHIVconsvX), such 
that no single junction is present more than once (Figure 3a). Two 
distinctly ordered mosaics are paired for the same vector modal-
ity (DNA, ChAdOx1, or MVA), thus the dose of each junction is 
halved for priming and boosting. Moreover, heterologous prime-
boost regimens never immunize twice with the same junction.
Comparable preclinical immunogenicity of the  
first- and second-generation vaccines
DNA fragments coding for the six tHIVconsvX immunogens were 
inserted into pSG2 plasmid DNA, ChAdOx126 (note that the first 
generation used ChAdV-63), and MVA. Because each is scram-
bled differently, forming a unique protein (Figure 3a), expression 
of all was confirmed in HeLa cells and protein levels were com-
parable (Figure 3b). Next, BALB/c mice were immunized with 
HIVconsv, or tHIVconsvX mosaic 1 or mosaic 2 vaccines alone, 
or with combined half doses of both with the aim of assessing 
overall immunogenicity. Separate comparisons were carried out 
for three administrations of plasmid DNAs and one administra-
tion of either recombinant MVAs or ChAdVs alone. Vaccine-
elicited, HIV-1-specific splenocytes were enumerated in an 
interferon (IFN)-γ ELISPOT assay using pools of 15-mer peptides 
overlapping by 11 aa (15/11) (Supplementary Figure  S8). The 
HIVconsv peptides were arranged into six pools P1–P6 23; P6 con-
tained an immunodominant H-2d-restricted epitope32 coupled 
to the C terminus of HIVconsv to facilitate preclinical develop-
ment. The two sets of peptides matching the two mosaics were 
organized into 10 pools, P1–P10, with variant peptide pairs com-
bined into the same pools, so that individual pool frequencies 
can be added to assess the total magnitude without counting 
responses to the same epitope twice. Induction of T cells by the 
Figure 2 Comparisons of epitope coverage using different vaccine 
strategies. Graph (a) shows a comparison of the global PTE coverage 
with 9/9 aa match, contrasting the coverage provided by a natural virus 
isolate HXB2 (light grey), a single consensus3 (dark grey), and bivalent 
mosaics (black). Four whole HIV-1 proteins that are commonly included 
in vaccines are compared with the regions included in the HIVconsv 
(first-generation) and tHIVconsvX (second-generation) immunogens. 
This calculation is not alignment based—all 9-mers in each protein in 
the original alignment are extracted, gaps are excluded and the frac-
tion of 9-mers that are covered (i.e., perfectly matched) by the vaccine 
candidate is calculated. This number is equivalent to the average num-
ber of epitopes per natural strain that are matched by a given vaccine 
candidate. (b) These graphs show the match with group M 9-mer PTE 
variant sequences for the regions of the second-generation tHIVconsvX 
bivalent mosaic (top left), those of the first-generation HIVconsv consen-
sus amino acid sequences (top right) and the rest of the HIV-1 proteome 
after removing the second-generation regions (bottom). The white verti-
cal gaps in the conserved-region vaccines figures indicate the boundar-
ies of each of the included regions. The top left and bottom figures are 
essentially a reordering of the data shown in Figure 1a, to enable a 
visual comparison of epitope coverage in the second-generation vaccine 
relative to the rest of the proteome.
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second- and first-generation vaccines was high and comparable, 
no matter in which order the conserved regions were scrambled 
in the tHIVconsvX proteins (Figure  4a). In tHIVconsvX pools 
P1 and P4, the likely immunodominant epitopes were mapped 
previously33 and the highest frequencies induced by the two 
stronger variants AMQMLKETI (mosaic 2) and LVGPTPVNI 
(mosaic 1) over their weaker variants AMQMLKDTI (mosaic 1) 
and LIGPTPVNI (mosaic 2) concurred with their presence in the 
particular mosaic. Notably, coadministration of mosaic 1 and 2 
resulted in frequencies halfway between those induced by indi-
vidual mosaics alone (Figure 4a). Thus, each mosaic on its own 
would induce one strong and one (relatively) weak response, but 
used together, the mosaic pair can respond strongly to both epi-
tope variants.
We also tested immunogenicity of the combined rChAdOx1 
prime-rMVA boost regimen, assessed the effect of mixed ver-
sus anatomically separate administration of the two mosa-
ics and immunized C57BL/6 mice, which lack the Th2 bias of 
BALB/c mice. Enhanced responses to tHIVconsvX in heterolo-
gous  prime-boost regimen relative to the single-vector delivery 
were consistently induced in both inbred strains (Figure  4b). 
The mixed and separate administrations of the two mosaic vari-
ants were not statistically separable (Figure 4c, left). Both CD8+ 
and CD4+ T cells were oligofunctional for production of IFN-γ, 
TNF-α, IL-2, and degranulation (CD107a) upon specific anti-
gen restimulation (Supplementary Figure S6). Importantly, no 
responses were detected to the pooled peptides spanning junc-
tional regions even using the potent rChAdOx1-rMVA regimen 
(Figure 4c, JXN).
Magnitude and breadth of responses to tHIVconsvX 
epitopes correlate with low viral load and high CD4+ 
cell count in treatment-naive patients
A key rationale for the conserved-region T-cell vaccine approach 
is the prediction that HIV-1+ patients whose CD8+ T cells recog-
nize the tHIVconsvX immunogen will have lower virus loads and 
their immune system will be more preserved than those lacking 
these responses. This is based on the argument that virus control is 
determined early in infection rather than during the chronic phase, 
because progressors do not spontaneously change into controllers 
during the chronic stage. To test this hypothesis, PBMC samples 
from 120 treatment-naive Japanese individuals with chronic HIV-1 
clade-B infection (Table 1) were tested for their ability to recog-
nize tHIVconsvX peptide pools P1–P10. The median frequencies 
of CD8+ T cells recognizing each of the ten tHIVconsvX peptide 
pools were determined using IFN-γ ELISPOT and flow cytometry. 
The total magnitude, or the sum of T-cell frequencies responding to 
individual peptides pools, showed a significant inverse correlation 
with plasma viral load (P = 0.0201) and a direct correlation with 
the CD4+ T-cell counts (P = 1.22 × 10-5) (Figure 5a). Correlations 
were also found for responses to individual peptide pools P3 and 
P9 for viral loads (Supplementary Figure S7a) and P1, P2, P3, 
P6, P8, and P9 for CD4+ cell counts (Supplementary Figure S7b). 
Furthermore, the protective potential of tHIVconsvX-specific T 
cells in treatment-naive patients was supported by statistically sig-
nificant correlations between the number of peptide pools (out of 
10) that the patients’ CD8+ T cells recognized and their viral load 
(P = 0.0032), and CD4+ cell counts (P = 4.87 × 10−5) (Figure 5a). 
Even after excluding patients with protective HLA B*52:01 and 
B*67:01 alleles34 (n  =  77), the magnitude and breadth of T-cell 
responses still significantly correlated with the CD4+ T-cell counts 
(P  =  4.48 × 10-5 and P  =  0.0001, respectively), but not with the 
plasma viral load (Figure  5b). Thus, the specificity of the anti-
HIV-1 CD8+ T cells, in particular the magnitude and breadth of 
CD8+ T cells recognizing conserved epitopes included in tHIV-
consvX, determine the suppression of chronic virus replication 
and impact the preservation of the patients’ immune system.
DISCUSSION
Here, we describe the design and construction of novel candidate 
T-cell vaccines against HIV-1. The major novelty in the design 
is the combination of conserved regions with the mosaic design 
such that both the computer-optimized vaccine immunogens and 
their vector delivery maximize effective targeting of global HIV-1 
variants by vaccine-elicited CD8+ T cells. This is shown by the very 
high level of perfect sequence matching between the vaccine and 
actual and potential epitope sequences across all the major clades 
of HIV-1. Thus, the conserved nature of the epitopes included in 
the vaccine makes immunogen responses more likely to be ini-
tially cross-reactive and less likely to be escaped. We confirmed 
Figure 3 Arrangement of regions and expressions of the tHIVconsvX 
immunogens. (a) Serial organization (scramble) of the six regions used 
to minimize induction T-cell responses by potentially newly formed 
junctional epitopes. These are irrelevant for protection, because they 
are not present in natural HIV-1 proteins. The delivery vectors, into 
which the individual immunogens were inserted for presentation to the 
immune system, are also indicated. Note that mosaic 1 and mosaic 2 
are always used together in the same vaccine dose. (b) Expression of 
individual tHIVconsvX proteins from the plasmid DNA, ChAdOx1, and 
MVA vaccine vectors. HeLa cells were either transfected with 2.5 µg of 
pSG2.tHIVconsv1 and pSG2.tHIVconsv2 for 2 days, infected with MVA.
tHIVconsv3 and MVA.tHIVconsv4 MOI of 5 for 1 day, or infected with 
ChAdOx1.tHIVconsv5 and ChAdOx1.tHIVconsv6 at MOI of 10 for 1 
day. Recombinant proteins were detected using primary mAb ID (91-5) 
followed by FITC-conjugated goat-antihuman IgG secondary antibody 
(green). DAPI stain shows the positions of cell nuclei (blue).
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expression of all six differentially scrambled immunogen proteins 
in human cells and demonstrated high T-cell immunogenicity of 
the tHIVconsvX regions in the absence of any junctional responses 
in two inbred mouse strains. This predicts that they will be as 
immunogenic in humans as was the first-generation HIVconsv 
vaccine, which generated uniquely strong T-cell responses in 
phase 1 vaccine trials23 (and T.H., unpublished). Furthermore, 
the advantages of the mosaic design shown previously in rhesus 
Figure 4 Comparable immunogenicity of the first- and second-generation of conserved-region vaccines in mice. Groups of six BALB/c mice 
were immunized with either the first- or second-generation immunogens as indicated below the graphs. The immunogens were vectored by 
DNA, MVA, or one of the chimpanzee adenoviruses ChAdV-63 (first generation) or ChAdOx1 (second generation) as shown above the graphs. 
 Vaccine-elicited, conserved-region-specific T cells were enumerated in a fresh unexpanded IFN-γ ELISPOT assay using 15-mer peptides overlapping 
by 11 amino acids assembled into 6 pools P1–P6 or 10 pools P1–P10 of over 30 peptides each corresponding to the first-(HIVconsv) and second 
 (tHIVconsvX)-generation vaccines, respectively. Graphs show (a) the totals (sum of all pools) of net T-cell frequencies as spot-forming units (SFU) 
per million of splenocytes for each vaccine modality indicated above the graphs and (b) the net frequencies of T cells recognizing individual peptide 
pools. (c) BALB/c and C57BL/6 mice were vaccinated using the rChAdV  prime-rMVA boost regimens using mixed or anatomically separated deliveries 
of the two mosaic immunogens. JXN indicates a pool of junctional peptides. Frequencies are shown as mean ± SEM (n = 6).
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monkeys13,14 and transgenic mice with HLA-A*02:01 presenta-
tion12 should enhance the magnitude, breadth, and depth of the 
induced CD8+ T-cell responses in human subjects, too. This will 
need to be tested in clinical trials in humans, who are the only 
relevant species for this level of detailed analysis. It is very encour-
aging that we found a correlation between the magnitude and 
breadth of CD8+ T-cell responses to the tHIVconsvX-conserved 
regions and low viral load and preservation of CD4+ T-cell counts 
in treatment-naive HIV-1+ patients.
Although substantial experimental progress was made with 
our first-generation conserved design, supporting the general con-
cept22,23,35 (and T.H., unpublished), the improvements in the sec-
ond-generation design are substantial enough to merit changing 
over. In summary, there is a clearly improved coverage of known 
group M variants by the second relative to the  first-generation 
regions and certainly compared to the rest of the HIV-1 pro-
teome (Figures 1 and 2). The first-generation design was based 
on a single consensus for each region, while the second genera-
tion utilizes complementing bivalent-mosaic proteins intended to 
be used together. While this increases the cost, there are several 
advantages. First, this improves the potential epitope coverage at 
the population level, as even the most conserved regions of HIV-1 
are somewhat variable reflecting the enormous overall HIV-1 
global variation. Also, eliciting T-cell responses that can recog-
nize common epitope variants may block relatively fit immune 
escape routes that otherwise may be used by the virus in vivo.11 
The second-generation vaccine is 12% longer than the first and 
so contains more potential epitopes (872 aa versus 778). Despite 
the additional length, the second generation spans regions that are 
more consistently conserved than the first (Figure 2). The second 
generation contains fewer segments (6 versus 14), hence fewer 
unnatural junctional domains that could misdirect the immune 
response. The first generation contained only 15 protective epi-
topes compared to 25 that have been associated with high viral 
load in large patient cohorts in South Africa, Peru, and Spain.24 
In contrast, the second generation contains 33 protective epitopes 
and only 3 associated with high viral load, and all the beneficial 
epitopes included in the vaccine are highly conserved (Figure 2a). 
Our selection of these regions is supported by a recent study of 401 
treatment-naive HIV-1+ patients in Japan, infected with B-clade 
virus. In that cohort, CD8+ T-cell responses to 13 epitopes were 
significantly associated with low viral load and high CD4+ cell 
counts,36 10 of these are present in tHIVconsvX as perfect 100% aa 
matches (Supplementary Table S1). Together, the matching to all 
M group viruses and the presence of protective epitopes from four 
geographically separated cohorts support the global relevance of 
this second-generation design.
HIV-1-induced CD8+ T cells can be compromised by virus 
escape and ultimately limited in their effectiveness,6,37,38 and past 
T-cell vaccine strategies have failed to induce protective immu-
nity.39,40 Thus, inducing “more of the same” CTL by vaccines will 
not advance the vaccine development. The second generation of 
T-cell vaccines described here should avoid induction of inef-
fective responses, focusing on those that are less likely to select 
escape and therefore control virus control better24,36 (and this 
study), targeting HIV-1’s “Achilles heel”. In natural infection, inef-
fective T-cell responses often dominate and may compete with 
the protective ones, reducing their relative magnitude and there-
fore impact.41 The tHIVconsvX-conserved mosaic proteins will 
focus T-cell responses toward conserved subdominant epitopes, 
by excluding the hypervariable regions of full-length HIV-1 pro-
teins that are often immunodominant both in natural infection41 
and in responses stimulated by previous vaccines.38,40 Further 
insights into definition of HIV-1 vulnerability recently suggested 
that association of high fitness cost with changes in functionally 
conserved regions may be further increased by considerations 
of structure stability.42–44 Nonetheless, the contribution of struc-
tural constraints on the top and above conservation will be a rel-
atively small fraction of the benefits gained already by focusing 
on conserved regions, which resulted from structural/functional 
requirements. In any case, conserved mosaic is currently the 
most developmentally and clinically advanced approach to tackle 
HIV-1 diversity and escape.
Immunogen delivery is also critical for induction of protective 
responses.1 While the design of the tHIVconsvX immunogens has 
a strong rationale, their presentation to the immune system has to 
induce potent CD8+ T-cell responses and memory, that will not be 
superseded by less protective primary T-cell responses after expo-
sure to HIV-1. The heterologous regimen of ChAdV and MVA 
(±DNA) currently stimulates the strongest CD8+ T cells of any 
nonreplicating subunit vaccines in humans.23,45,46 ChAdOx1 has 
low seroprevalence in humans,26 and recombinant ChAdVs have 
been safely used in over 1,500 volunteers including African infants 
(Adrian Hill, University of Oxford, personal communication). 
The comparable immunogenicity of the first and second genera-
tions of conserved vaccines in mice suggests that in humans, the 
second generation will be as potent as the first generation was,23 
with all the advantages of second-generation design.
There is a strong rationale for using the conserved mosaic 
tHIVconsvX vaccines in both prophylactic and therapeutic 
settings. For prevention, tHIVconsvX vaccines by matching 
transmitted/founder viruses will aim to decrease HIV-1 acqui-
sition, eradicate HIV-1 early in infection or establish very good 
virus control, and will complement any broadly neutralizing 
 antibodies-eliciting strategies.2 Therapeutic vaccines aim to either 
control HIV-1 replication without the need of antiretroviral drugs 
or eradicate HIV-1 from the body completely following reacti-
vation of latent HIV-1 genomes.20,47 The tHIVconsvX strategy is 
Table 1 Characteristics of the treatment-naive HIV-1 clade B-positive 
patient cohort
N 120
Sex, male (%) 97
Age, years–median (IQR) 37 (30–43)
Known duration of infection, years–median (IQR) Not known, minimum 
a few years
CD4+ T cell counts, cell/μl–median (IQR) 267 (77–419)
Plasma viral loada, copies/ml–median (IQR) 65,500  
(23,000 - 190,000)
Known protective alleles (B*52:01, B*67:01), nb 43
Clade B 120/120
aCobas TaqMan HIV-1 real-time PCR version 2.0 assay (Roche Diagnostics, NJ, USA)
bReference 34
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particularly suited for the therapeutic use, because refocusing 
cytotoxic T-cell effectors on the conserved regions of HIV-1 is 
greatly preferable to reactivating T cells that have already failed 
to control the virus and selected for escape mutations retained in 
provirus reservoirs.20,47 Therapeutic approaches may not require 
coinduction of broadly neutralizing antibodies.
Vaccine-induced CD8+ T cells will have to suppress trans-
mitted/founder HIV-1 or reactivated HIV-1 replication,2 acting 
efficiently from the onset of infection/reactivation.5,6 The correla-
tion in treatment-naive patients of the magnitude and breadth of 
tHIVconsvX-specific CD8+ T cells with high CD4+ T-cell counts 
and with low virus loads indicates that these responses are benefi-
cial.24,28,36,37 High CD4+ counts, the best indicator of slowed disease 
progression, remained significantly correlated even after excluding 
patients with known protective HLA alleles. Thus, benefits of tHIV-
consvX CD8+ T-cell responses could reach the whole population.
Figure 5 tHIVconsvX-specific CD8+ T-cell responses are beneficial in chronically infected treatment-naive patients. PBMCs responsive to tHIV-
consvX peptide pools P1–P10 from treatment-naive patients in Japan chronically infected with HIV-1 clade B were enumerated in an IFN-γ ELISPOT assay 
and the frequencies of CD8+ and CD4+ T cells were determined by flow cytometry. Correlations between the magnitude (top) or breadth (bottom) and 
the viral load (left) or CD4+ cell counts (right) were statistically analyzed using Spearman’s rank test. The P values are given above individual graphs. (a) 
Correlations in all patients (n = 120) and (b) in a subgroup of patients without the two known protective HLA alleles B*52:01 and B*67:01 (n = 77).
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This improved approach to targeting T-cell responses on bio-
logically highly sensitive regions of HIV-1 proteins, common to 
majority of global variants, early for prophylaxis or refocusing for 
treatment, merits clinical evaluation and could lead to develop-
ment of a truly global HIV-1 vaccine.
MATERIALS AND METHODS
Synthetic genes for tHIVconsvX. Six DNA fragments carrying the six tHIV-
consvX open-reading frame were synthesized (Life Technologies) using 
humanized codons and were preceded by a consensus Kozak sequence at 
−6 nucleotides to maximize protein expression.
Construction of plasmid pSG2.tHIVconsv1 and pSG2.tHIVconsv2 
vaccines. For plasmid DNA, the backbone of pSG2 was used with the 
enhancer/intron A/human cytomegalovirus promoter immediate early 
promoter cassette, bovine growth hormone polyadenylation site and genes 
tHIVconsv1 and tHIVconsv2 were inserted to construct vaccine compo-
nents pSG2.tHIVconsv1 and pSG2.tHIVconsv2. The plasmid DNAs for 
immunizations were prepared using the Endo-Free Gigaprep (Qiagen) and 
stored at −20 °C until use.
Construction of MVA.tHIVconsv3 and MVA.tHIVconsv4 vaccines. The 
parental nonreplicating MVA originates directly from Professor Anton 
Mayr, passage 575 dated 14 December 1983. The tHIVconsv3 and tHIV-
consv4 genes were cloned into transfer plasmid p856MVA-GFP-TD-mH5 
under control of the modified H5 promoter. Through homologous recom-
bination, the expression cassettes were directed into the thymidine kinase 
locus on the MVA genome. The initially coinserted green fluorescent pro-
tein marker was removed by subsequent transdominant recombination 
to generate markerless vaccine components MVA.tHIVconsv3 and MVA.
tHIVconsv4. Recombinant MVAs were made as described elsewhere. 
Briefly, chicken embryo fibroblast cells grown in Dulbeco’s Modified Eagle’s 
Medium supplemented with 10% FBS, penicillin/streptomycin and glu-
tamine (DMEM 10) were infected with parental MVA at multiplicity of 
infection (MOI) 1 and transfected using Superfectin (Qiagen) with 3 µg 
of  p4016MVA-GFP-TD-mH5.tHIVconsv3 or p4065MVA-GFP-TD-mH5.
tHIVconsv4. The cell lysate from this recombination was harvested and used 
to infect chicken embryo fibroblast. These cells were MoFlo single-cell sorted 
into 96-well plates and these were used to culture recombinant virus upon 
addition of fresh chicken embryo fibroblast. Those wells containing suitably 
infected cells were harvested and screened by PCR to confirm identity and 
test purity. Plaque picking was performed until the culture was free of paren-
tal virus, as determined by PCR. The virus was then prepared in bulk and 
purified on a 36% sucrose cushion, titred and stored at –80 °C until use.
Construction of ChAdOx1.tHIVconsv5 and ChAdOx1.tHIVconsv6 vac-
cines. ChAdOx1 is derived from ChAdV isolate Y25 of group E adenovi-
ruses and preexisting antibodies to group E are rare in human populations. 
Its genome modifications include removal of the E1, E3, and a substitu-
tion of simian region E4 with the human adenovirus 5 E4 orf4 and orf6/7 
genes. For the generation of recombinant ChAdOx1s, the tHIVconsv5 and 
tHIVconsv6 genes were subcloned under the control of the human cyto-
megalovirus immediate early promoter into plasmid pENTR4_Mono and 
inserted at the E1 locus of the ChAdOx1 genome by GalK recombineer-
ing. Recombinant ChAdOx1 vaccines were rescued by transfection of 
HEK293A T-Rex cells using linearized plasmid and grown in suspension 
culture of HEK 293 cells. The presence of the transgene and absence of 
contaminating empty parental adenovirus was confirmed by PCR. The 
virus was titred to obtain infectious units per milliliter, assayed by spec-
trophotometry to quantify the number of virus particles per milliliter and 
stored at –80 °C until use.
Immunofluorescent staining for tHIVconsvX vaccines. First, DNA 
transfection was used to identify a primary anti-Gag p24 mAb, which 
recognized both mosaic variants. This was then used to confirm 
expression of the other four immunogen proteins expressed in recom-
binant virus-infected human cells. Briefly, HeLa cells were transfected 
with 2.5 µg of pSG2.tHIVconsv1 and pSG2.tHIVconsv1 for 48 hours, 
using Lipofectamine 3000 (Invitrogen), according to the manufacturer’s 
specifications. For MVA.tHIVconsv3 and MVA.tHIVconsv4, HeLa cells 
(ATCC, mycoplasmafree) were infected at MOI of 5 for 2 hours at 37 °C, 
5% CO2 in serum-free media. Following infection, the cells were washed 
with phosphate buffered saline (PBS) and incubated in 3 ml of complete 
DMEM media for 24 hours. Infection with ChAdOx1.tHIVconsv5 and 
ChAdOx1.tHIVconsv6 were conducted in a similar way, except that a 
MOI of 10 was used. At the end of overnight incubation, the cells were 
washed twice with ice cold PBS and fixed for 10 minutes on ice with 10% 
neutral buffered formalin solution containing 4% formaldehyde (Sigma). 
The fixed cells were incubated at room temperature for 20 minutes, then 
washed three times with PBS and permeabilized with 0.2% Triton (TX-
100) for 5 minutes at room temperature. Cells were washed again, blocked 
with 1% bovine serum albumin in PBS for 30 minutes and incubated over-
night with a 1:200 dilution of the primary antibody (NIH reagent mAb ID 
(91-5), catalogue #1238). The cells were washed three times for 15 min-
utes each, using PBS and stained with 1:200 dilution of FITC-conjugated 
goat-antihuman IgG secondary antibody (Millipore) for 2 hours at room 
temperature. The cells were washed three times as before and the cover-
slips mounted on microscope slides using Vectashield DAPI nuclear stain 
mounting media (Vector laboratories). The slides were examined on a 
fluorescence microscope (Leica DMI 3000B) and images were analyzed 
with the ImageJ program.
Mice and immunization regimens. Six-week-old female BALB/c or 
C57BL/6 mice were purchased from Harlan Laboratories (UK) and 
housed at the Functional Genomics Facility, University of Oxford. Groups 
of six animals are a standard group size for vaccine initial vaccine experi-
ments using inbred mouse strains. Mice were immunized intramuscularly 
under general anaesthesia either with 100 μg of plasmid DNA, 108 infec-
tious units of rChAdOx1s, 5 × 106 plaque-forming units of rMVAs. In the 
combined regimens of mosaics 1 and 2, half a dose for each vaccine type 
was used injecting mosaic 1 and 2 into the left and right hind quadriceps, 
respectively. Mice were sacrificed 2 weeks after the last rChAdOx1 and 1 
week after the last rMVA or DNA. All procedures and care were approved 
by the local Research Ethics Committee, University of Oxford and con-
formed strictly to the United Kingdom Home Office Guidelines under the 
Animals (Scientific Procedures) Act 1986. Experiments were conducted 
under Project License 30/2833 held by T.H.
Peptides. Over 90% pure 15-mer peptides overlapping by 11 aa (15/11) 
spanning the entire HIVconsv, mosaic 1, and mosaic 2 six regions were 
used in IFN-γ ELISPOT assay to assess the vaccine immunogenicity. One 
hundred and ninety-nine HIVconsv-derived peptides (Ana Spec, USA) 
were assembled into six pools P1–P6. Two hundred and 201 peptides cor-
responding to the six regions of mosaic 1 and mosaic 2, respectively, were 
assembled into 10 pools P1–P10 of between 34 and 47 peptides in a way 
that variant peptides were always present in the same pool. Thirty one 
16-mer peptides corresponding to 30 junctions of tHIVconsvX and the tPA 
leader as 22-mer were assembled into pool JXN. Supplementary Figure 
S8 illustrates the peptide derivation. Individual peptides were dissolved 
in DMSO at a concentration of 20 mg/ml and stored at −80 °C. Working 
stocks of 4 mg/ml were prepared by diluting 20 mg/ml stocks with PBS. 
Peptides were used in assays at a final concentration of 2 μg/ml.
Murine IFN-γ ELISPOT assay. The ELISPOT assay was performed using 
the Mouse IFN-γ ELISpot kit (Mabtech) according to the manufacturer’s 
instructions. Immune splenocytes were collected and tested separately 
from individual mice. Spots were visualized using sequential applications 
of a biotin-conjugated secondary anti-IFN-γ mAb (R4-6A2, Rat IgG1), an 
alkaline phosphatase and a chromogenic substrate (Bio-Rad) and counted 
using the AID ELISpot Reader System (Autoimmun Diagnostika).
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HIV-1+ subjects. One hundred and twenty treatment-naive Japanese indi-
viduals with chronic HIV-1 clade-B infection were enrolled in the National 
Center for Global Health and Medicine from 2011 to 2012. This study 
was approved by the ethics committees of the National Center for Global 
Health and Medicine and Kumamoto University. The study was conducted 
according to the principles of the Declaration of Helsinki (2008) and com-
plied with the International Conference on Harmonization Good Clinical 
Practice guidelines.
Human IFN-γ ELISPOT assay. Peptide pools P1–P10 at a concentration of 
1.5 μg/ml of each peptide and PBMCs separated from whole blood at 1 × 105 
cells/well were added to 96-well polyvinylidene plates (Millipore, Bedford, 
MA) that had been precoated with 5 mg/mL anti-IFN-γ mAb 1-D1K 
(Mabtech, Stockholm, Sweden). The plates were incubated at 37 °C in 5% 
CO2 for 16 hours and washed with PBS before the addition of biotinylated 
anti-IFN-γ Mab (Mabtech) at 1 mg/ml at room temperature for 90 minutes. 
The plates were then washed with PBS, incubated with streptavidin-conju-
gated alkaline phosphatase (Mabtech) at room temperature for 60 minutes, 
washed with PBS, and individual cytokine-producing units were detected as 
dark spots after a 20-minute reaction with  5-bromo-4-chloro-3-idolyl phos-
phate and nitro blue tetrazolium using an alkaline phosphatase-conjugate 
substrate (Bio-Rad, Richmond, CA, USA). Spot-forming units were counted 
with an Eliphoto-Counter (Minerva Teck, Tokyo, Japan). The frequencies of 
responding cell were expressed as a number of spot-forming units/106 CD8+ 
T cells by measuring frequency of CD8+ T cells using a flow cytometry. A 
mean ± 2 SD of the spot number of samples from 12  HIV-1-naive individu-
als for these peptides was <176 spots/106 CD8+ T cells. Therefore, we defined 
>200 spot-forming units/106 CD8+ T cells as positive responses. Ninety six 
volunteers were used based on availability and provided sufficient power to 
detect statistically significant differences for a proportion of samples.
Statistical analysis. Statistical analyses were performed using Graph Pad 
Prism version 5. Simple comparisons were performed using two-way 
Student’s t-test. Multiple comparisons were performed using the Kruskal–
Wallis test with Dunn’s multiple comparison posttest for nonparametric 
data. Correlations between the breadths or the magnitudes and pVL or 
CD4 counts were statistically analyzed using Spearman’s rank test. For 
comparison of two groups, two-tailed Mann–Whitney’s U-tests were per-
formed. A P value <0.05 was considered significant.
SUPPLEMENTARY MATERIAL
Figure S1. Comparing coverage by Gag conserved regions of the 
first- and second-generation vaccines.
Figure S2. Comparing coverage of the second generation (a) and 
original (b) conserved region vaccines.
Figure S3. Examples of the diversity of three experimentally defined 
epitopes.
Figure S4. Known epitopes in the LANL-HSD recognized by human 
CD8+ and CD4+ T cells in individual HIV-1 proteins as of 2013.
Figure S5. Amino acid sequences of the two complementing mosaic 
regions and their amino acid differences.
Figure S6. Functionality of tHIVconsvX-specific CD8+ and CD4+ 
T cells induced by the rChAdOx1-prime rMVA-boost regimen.
Figure S7. Correlation between magnitude of responses in IFN-γ 
ELISPOT assay to individual tHIVconsvX peptide pools and plasma viral 
load or CD4+ T cell count in treatment-naïve HIV-1+ patients (n = 120).
Figure S8. Peptide pools used for immune monitoring.
Table S1. Protective Japanese epitopes in the tHIVconsvX vaccines.
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